Alternativen zu Tirzepatide

An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.

Activates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.

An Ayurvedic herb studied for supporting blood-sugar control and for temporarily blunting sweet taste and sugar cravings.

An FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.

Vitamin-like compound studied for hormonal and metabolic balance. Best evidence is for PCOS and gestational-diabetes prevention (multiple meta-analyses, though recent high-quality trials are mixed); anxiety/OCD data are older and thinner.

First-line natural treatment for PCOS that improves insulin sensitivity and ovulation — also reduces anxiety, panic, and OCD symptoms.

An investigational ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. Honest appraisal: the phase-2 data are strong and the first phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it is INVESTIGATIONAL and not yet approved as a general weight-loss medicine, has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), and the expected thyroid C-cell class warning and long-term outcomes are unsettled. It is NOT a dietary supplement; listed here for reference only.

An investigational once-weekly injectable GLP-1 and glucagon receptor dual agonist (an oxyntomodulin analogue, IBI362/LY3305677) developed mainly in China by Innovent and Eli Lilly for obesity and type 2 diabetes. Honest appraisal: real phase-2 and phase-3 randomized trials show clinically meaningful weight loss (~12-17% at higher doses) and HbA1c reduction, but the evidence is almost entirely single-region (Chinese) and recent. It was approved in China in 2025 — it is NOT FDA-approved and is not available or approved in the West. It is a prescription drug, not a dietary supplement.